Table 1. Pharmacological effects of piceatannol and resveratrol on in vivo models of renal diseases.
Compound | Effects | Target organ | Animal models | References |
---|---|---|---|---|
Piceatannol | Mild renoprotective effect | Kidney | Obese Zucker rats | Llarena et al., 2016 [27] |
Piceatannol | Preventive graft rejection | Kidney | ACI-to-Lewis rats | Fernandez et al., 2002 [26] |
Resveratrol | • RenoprotectionReduction of renal interstitial fibrosis • Inhibition of EMT and renal fibrosis |
Kidney | UUO rats | • Yang et al., 2016 [29] • Zhang et al., 2016 [67] • Bai et al., 2014 [68] |
Resveratrol | Attenuation of renal interstitial fibrosis | Kidney | db/db mice | • He et al., 2016 [28] • Yan et al., 2016 [69] |
Resveratrol | Amelioration of renal injury and tubulointerstitial fibrosis | Kidney | SHR rats | Xue et al., 2016 [70] |
Resveratrol captopril | Improvement of aortic remodeling and fibrosis | Aorta | 2K1C Goldblatt rats | Natalin et al., 2016 [71] |
Resveratrol | • Attenuation of renal injury and fibrosis • Protective renal fibrosis |
Kidney | • UUO mice or I/R injury mice • UUO mice • UUO mice |
• Xiao et al., 2016 [30] • Liang et al., 2014 [72] • Li et al., 2010 [48] |
Resveratrol | Protective renal fibrosis | Kidney | 5/6th nephrectomized rats | Huang et al., 2014 [73] |
Resveratrol | • Attenuation of diabetic nephropathy • Reduction of renal fibrosis |
Kidney | Streptozotocin-treated rats | • Wen et al., 2013 [74] • Chen et al., 2011 [75] |
Resveratrol | Renoprotection | Kidney | Unilateral nephrectomized rats | Sener at al., 2006 [76] |
UUO: unilateral ureteral obstruction
EMT: epithelial-mesenchymal transition
I/R injury: ischemia-reperfusion injury
db/db: spontaneous type 2 diabetic animal model
SHR: spontaneously hypertensive rats
2K1C: two-kidney, one-clip model